The study focused on the rheumatoid arthritis drug, Enbrel, the nasal allergy medication Nasonex, and the irritable bowel syndrome medicine, Zelnorm.

• 该研究着重关注风湿性关节炎药物---治疗类风湿性关节炎的新药恩博，治疗鼻腔过敏新药内舒那，以及刺激性肠道综合症药物泽马可。